ATE373671T1 - Aminooxy-modifizierte oligonukleotide - Google Patents
Aminooxy-modifizierte oligonukleotideInfo
- Publication number
- ATE373671T1 ATE373671T1 AT98908488T AT98908488T ATE373671T1 AT E373671 T1 ATE373671 T1 AT E373671T1 AT 98908488 T AT98908488 T AT 98908488T AT 98908488 T AT98908488 T AT 98908488T AT E373671 T1 ATE373671 T1 AT E373671T1
- Authority
- AT
- Austria
- Prior art keywords
- aminooxy
- modified oligonucleotides
- moieties
- oligonucleotide
- oligonucleotides
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3714397P | 1997-02-14 | 1997-02-14 | |
| US09/016,520 US6127533A (en) | 1997-02-14 | 1998-01-30 | 2'-O-aminooxy-modified oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE373671T1 true ATE373671T1 (de) | 2007-10-15 |
Family
ID=26688714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98908488T ATE373671T1 (de) | 1997-02-14 | 1998-02-13 | Aminooxy-modifizierte oligonukleotide |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6127533A (de) |
| EP (1) | EP0977767B1 (de) |
| JP (1) | JP4440346B2 (de) |
| KR (1) | KR100399743B1 (de) |
| AT (1) | ATE373671T1 (de) |
| AU (1) | AU740799B2 (de) |
| CA (1) | CA2278715C (de) |
| DE (1) | DE69838449T2 (de) |
| WO (1) | WO1998035978A1 (de) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| ATE247128T1 (de) | 1993-09-03 | 2003-08-15 | Isis Pharmaceuticals Inc | Aminoderivatisierte nukleoside und oligonukleoside |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US6172209B1 (en) * | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6639062B2 (en) * | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| US6576752B1 (en) * | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| WO1999060012A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| US6326478B1 (en) | 1998-07-08 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6887990B1 (en) * | 1999-02-05 | 2005-05-03 | Amersham Biosciences Corp | Method for deprotecting oligonucleotides |
| US6207819B1 (en) * | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| ES2234563T5 (es) * | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US6140124A (en) * | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
| US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| US6277982B1 (en) | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
| US20050118618A1 (en) * | 1999-08-30 | 2005-06-02 | Dale Roderic M. | Method for detecting nucleic acid sequences |
| DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US6686461B1 (en) | 2000-03-22 | 2004-02-03 | Solulink Bioscience, Inc. | Triphosphate oligonucleotide modification reagents and uses thereof |
| JP3425623B2 (ja) | 2000-04-03 | 2003-07-14 | 東京工業大学長 | Ｄｎａの蛍光標識プローブ、蛍光標識プラスミド |
| US7423142B2 (en) * | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7767802B2 (en) * | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US6825338B2 (en) * | 2001-03-30 | 2004-11-30 | Isis Pharmaceuticals, Inc. | Labeled oligonucleotides, methods for making same, and compounds useful therefor |
| EP1401850A1 (de) | 2001-06-20 | 2004-03-31 | Nuevolution A/S | Nukleosidderivate zur herstellung einer verbindungsbibliothek |
| US10731151B2 (en) | 2002-03-15 | 2020-08-04 | Nuevolution A/S | Method for synthesising templated molecules |
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| EP1539980B1 (de) | 2002-08-01 | 2016-02-17 | Nuevolution A/S | MEHRSTUFENSYNTHESE VON MIT MATRIZEN ASSOZIIERTE MOLEKüLEN |
| US20040038331A1 (en) * | 2002-08-23 | 2004-02-26 | Reddy M. Parameswara | Solid phase synthesis of biomolecule conjugates |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2004046321A2 (en) | 2002-11-15 | 2004-06-03 | Trustees Of Boston University | Cis/trans riboregulators |
| US20040115634A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Modulation of stat 6 expression |
| JP4579911B2 (ja) | 2003-06-03 | 2010-11-10 | アイシス・ファーマシューティカルズ・インコーポレイテッド | スルビビン発現の調節 |
| AU2004263830B2 (en) | 2003-06-13 | 2008-12-18 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| EP2256201A3 (de) | 2003-09-18 | 2012-07-04 | Isis Pharmaceuticals, Inc. | Modulation der eIF4E expression |
| US11118215B2 (en) | 2003-09-18 | 2021-09-14 | Nuevolution A/S | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
| WO2005056761A2 (en) * | 2003-12-05 | 2005-06-23 | Massachusetts Institute Of Technology | REAGENTS AND METHODS FOR IDENTIFICATION OF RNAi PATHWAY GENES AND CHEMICAL MODULATORS OF RNAi |
| US20060058255A1 (en) * | 2004-03-01 | 2006-03-16 | Jianzhu Chen | RNAi-based therapeutics for allergic rhinitis and asthma |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| ES2423060T3 (es) * | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| JP2007531794A (ja) | 2004-04-05 | 2007-11-08 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの合成および精製に使用する方法および反応試薬 |
| AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| AU2005327506B2 (en) | 2004-10-20 | 2010-07-08 | Antisense Therapeutics Ltd | Antisense modulation of integrin alpha4 expression |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US7244829B2 (en) * | 2004-11-08 | 2007-07-17 | Gem Pharmaceuticals, Llc | Compositions and processes for preparing 13-deoxy-anthracyclines |
| US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
| US20060166234A1 (en) | 2004-11-22 | 2006-07-27 | Barbara Robertson | Apparatus and system having dry control gene silencing compositions |
| US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
| US7585968B2 (en) | 2005-03-28 | 2009-09-08 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to thymus and activation-regulated chemokine (TARC) |
| WO2006113743A2 (en) * | 2005-04-18 | 2006-10-26 | Massachusetts Institute Of Technology | Compositions and methods for rna interference with sialidase expression and uses thereof |
| JP5111385B2 (ja) * | 2005-10-28 | 2013-01-09 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ハンチンチン遺伝子の発現を抑制するための組成物および方法 |
| CA2626584A1 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
| US20100069461A1 (en) | 2005-11-09 | 2010-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
| PT3305900T (pt) | 2005-12-01 | 2021-10-27 | Nuevolution As | Métodos de codificação enzimática para síntese eficaz de bibliotecas grandes |
| WO2007067733A2 (en) * | 2005-12-09 | 2007-06-14 | Massachusetts Institute Of Technology | Compositions and methods to monitor rna delivery to cells |
| WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
| CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| JP5630998B2 (ja) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | 機能的粒子のためのポリマー |
| EP2030015B1 (de) * | 2006-06-02 | 2016-02-17 | President and Fellows of Harvard College | Neugestaltung von proteinoberflächen |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
| AU2007299705B2 (en) | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| US20110294782A1 (en) | 2006-11-10 | 2011-12-01 | Massachusetts Institute Of Technology | Small molecule pak inhibitors |
| WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| EP2134830A2 (de) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oszillations-zellkultur-bioreaktor |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| JP2010523595A (ja) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ（アミノ酸）ターゲッティング部分 |
| CA2689310A1 (en) * | 2007-05-30 | 2008-12-11 | Brigham Young University | Protein kinase-binding nucleosides and associated methods |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| US7732659B2 (en) * | 2007-11-20 | 2010-06-08 | Genetic Services, Inc. | Injecting Drosophila embryos |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| JP2011523353A (ja) * | 2008-04-28 | 2011-08-11 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
| EP2313505A2 (de) * | 2008-07-15 | 2011-04-27 | F. Hoffmann-La Roche AG | Zusammensetzungen und verfahren zur expressionshemmung von tgf-beta-rezeptorgenen |
| US20100076183A1 (en) | 2008-09-22 | 2010-03-25 | Dellinger Douglas J | Protected monomer and method of final deprotection for rna synthesis |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| WO2010055041A1 (en) * | 2008-11-17 | 2010-05-20 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of factor vii genes |
| US20110294870A1 (en) * | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| AU2010211133A1 (en) | 2009-02-03 | 2011-07-21 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of PTP1B genes |
| JP5463055B2 (ja) * | 2009-02-27 | 2014-04-09 | 公益財団法人相模中央化学研究所 | フタルイミド誘導体及びそれらの製造方法 |
| US8067526B2 (en) * | 2009-03-27 | 2011-11-29 | Nof Corporation | Method for producing polyoxalkylene derivative |
| EP2424877A4 (de) | 2009-04-28 | 2013-01-02 | Harvard College | Suprageladene proteine zur zellpenetration |
| JP2012526533A (ja) * | 2009-05-15 | 2012-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | グルココルチコイドレセプター（ｇｃｒ）遺伝子の発現を阻害するための組成物及び方法 |
| US8951981B2 (en) * | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| AR078921A1 (es) * | 2009-11-09 | 2011-12-14 | Hoffmann La Roche | Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10 |
| US20110152349A1 (en) * | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
| US20110196016A1 (en) * | 2010-02-05 | 2011-08-11 | Anke Geick | Compositions and Methods for Inhibiting Expression of IKK2 Genes |
| EP3540059A1 (de) | 2010-04-16 | 2019-09-18 | Nuevolution A/S | Bifunktionelle komplexe und verfahren zur herstellung sowie verwendung derartiger komplexe |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP3434772A3 (de) | 2010-10-18 | 2019-03-20 | Arrowhead Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen |
| BR112013018918A2 (pt) | 2011-01-24 | 2016-10-04 | Anterios Inc | composições de nanopartículas |
| US20120328701A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| EP2694524B1 (de) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2 '-o-aminooxymethylnukleosidderivate zur verwendung bei der synthese und modifizierung von nukleosiden, nukleotiden und oligonukleotiden |
| US8916696B2 (en) | 2011-06-12 | 2014-12-23 | City Of Hope | Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use |
| EA024762B9 (ru) | 2011-06-30 | 2017-04-28 | Эрроухэд Рисерч Корпорейшн | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| EP3052464B1 (de) | 2013-10-04 | 2020-04-15 | Novartis AG | 3 endkappen für rnai-mittel zur verwendung in der rna-interferenz |
| HK1221912A1 (zh) | 2013-10-04 | 2017-06-16 | Novartis Ag | 用於治疗乙肝病毒的有机化合物 |
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| KR102524543B1 (ko) | 2014-06-10 | 2023-04-20 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드 |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| US20180153884A1 (en) | 2015-05-31 | 2018-06-07 | Curegenix Corporation | Combination compositions for immunotherapy |
| MX2018000412A (es) | 2015-07-10 | 2018-03-14 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| WO2017099579A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| US10369167B2 (en) | 2016-11-01 | 2019-08-06 | City Of Hope | Continuously expressed therapeutic RNAs for targeted protein binding and methods for their use |
| JP7576835B2 (ja) | 2018-03-22 | 2024-11-01 | ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 自己免疫疾患および癌を治療するための可溶性インターロイキン７受容体（ｓＩＬ７Ｒ）調節療法 |
| CA3158528A1 (en) | 2019-12-23 | 2021-07-01 | Jim SWILDENS | Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease |
| EP4479535A1 (de) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide-oligonukleotide zur nukleinsäureeditierung bei der behandlung von hypercholesterinämie |
| CN118165059A (zh) * | 2024-03-11 | 2024-06-11 | 生工生物工程（上海）股份有限公司 | 一种n2-c6氨基修饰脱氧鸟苷单体的合成方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5430136A (en) * | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| WO1986005519A1 (en) * | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0260032B1 (de) * | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere |
| US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| JPH03503894A (ja) * | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド ｎ‐アルキルホスホラミデート |
| DE68927417T2 (de) * | 1988-04-27 | 1997-03-20 | Isis Pharmaceutical Inc | Oligoribonukleotid-Derivate und ihre Anwendung als antivirale Mittel |
| US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) * | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| DE3916871A1 (de) * | 1989-05-24 | 1990-11-29 | Boehringer Mannheim Gmbh | Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren |
| EP0476071A4 (en) * | 1989-06-05 | 1992-11-04 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides and methods for preparing the same |
| DE69034150T2 (de) * | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5264562A (en) * | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5177198A (en) * | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5459255A (en) * | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5457191A (en) * | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5591623A (en) * | 1990-08-14 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5506351A (en) * | 1992-07-23 | 1996-04-09 | Isis Pharmaceuticals | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
| WO1992003568A1 (en) * | 1990-08-13 | 1992-03-05 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| KR927003044A (ko) * | 1990-01-11 | 1992-12-17 | 크리스토퍼 케이. 미라벨리 | Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법 |
| US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5359051A (en) * | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
| US5514786A (en) * | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
| US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5321131A (en) * | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| DE4037363A1 (de) * | 1990-04-09 | 1991-10-10 | Europ Lab Molekularbiolog | 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten |
| US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| WO1991018997A1 (en) * | 1990-05-25 | 1991-12-12 | Gilead Sciences, Inc. | Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna |
| US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5386023A (en) * | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5223618A (en) * | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| JPH0874B2 (ja) * | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5138045A (en) * | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| ES2104717T3 (es) * | 1990-08-16 | 1997-10-16 | Isis Pharmaceuticals Inc | Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus. |
| US5442049A (en) * | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| US5214134A (en) * | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| JPH06505704A (ja) * | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ，インコーポレイテッド | 改変ヌクレオシド間結合 |
| US5242906A (en) * | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
| WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| ATE186072T1 (de) * | 1991-06-14 | 1999-11-15 | Isis Pharmaceuticals Inc | Antisense-oligonukleotid-inhibition des ras-gen |
| US5582986A (en) * | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| DE69233046T2 (de) * | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5464746A (en) * | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| US5543507A (en) * | 1992-03-05 | 1996-08-06 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
| US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| ATE299509T1 (de) * | 1992-07-23 | 2005-07-15 | Isis Pharmaceuticals Inc | Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
| GB9304618D0 (en) * | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| US5571902A (en) * | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5510476A (en) * | 1994-07-07 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Carbocation scavenging during oligonucleotide synthesis |
| US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
-
1998
- 1998-01-30 US US09/016,520 patent/US6127533A/en not_active Expired - Lifetime
- 1998-02-13 DE DE69838449T patent/DE69838449T2/de not_active Expired - Lifetime
- 1998-02-13 EP EP98908488A patent/EP0977767B1/de not_active Expired - Lifetime
- 1998-02-13 WO PCT/US1998/002405 patent/WO1998035978A1/en not_active Ceased
- 1998-02-13 KR KR10-1999-7007378A patent/KR100399743B1/ko not_active Expired - Lifetime
- 1998-02-13 JP JP53583898A patent/JP4440346B2/ja not_active Expired - Lifetime
- 1998-02-13 AU AU66513/98A patent/AU740799B2/en not_active Expired
- 1998-02-13 CA CA002278715A patent/CA2278715C/en not_active Expired - Lifetime
- 1998-02-13 AT AT98908488T patent/ATE373671T1/de not_active IP Right Cessation
-
2000
- 2000-01-05 US US09/477,902 patent/US6194598B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6127533A (en) | 2000-10-03 |
| DE69838449D1 (de) | 2007-10-31 |
| JP4440346B2 (ja) | 2010-03-24 |
| JP2001512457A (ja) | 2001-08-21 |
| AU6651398A (en) | 1998-09-08 |
| US6194598B1 (en) | 2001-02-27 |
| CA2278715A1 (en) | 1998-08-20 |
| EP0977767A4 (de) | 2003-04-23 |
| EP0977767A1 (de) | 2000-02-09 |
| KR100399743B1 (ko) | 2003-09-29 |
| CA2278715C (en) | 2008-12-02 |
| EP0977767B1 (de) | 2007-09-19 |
| WO1998035978A1 (en) | 1998-08-20 |
| AU740799B2 (en) | 2001-11-15 |
| DE69838449T2 (de) | 2008-06-12 |
| KR20000071091A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE373671T1 (de) | Aminooxy-modifizierte oligonukleotide | |
| ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| BR9707529A (pt) | Oligunucleotìdeo especificamente hibridizável com dna ou rna. | |
| EP0963997A4 (de) | Nucleotidanaloga | |
| DK1178999T3 (da) | L-RIBO-LNA-analoger | |
| DE69806003D1 (de) | Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen | |
| ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
| ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
| ATE196912T1 (de) | Propargylethoxyamino nucleotide | |
| RU98105786A (ru) | Модифицированные праймеры | |
| ES2243007T3 (es) | Sintesis quimica completa y sintesis de genes de genomas. | |
| EP0637316A4 (de) | Antisense-oligonukleotide-inhibitoren von papillomaviren. | |
| ATE432284T1 (de) | Einen starren linker enthaltende nukleotide | |
| ATE121416T1 (de) | Oligonukleotid-analoge. | |
| EP1013661A4 (de) | Bicyclonukleosid- und oligonukleotid-analoga | |
| ATE324440T1 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
| Pitulle et al. | Initiator oligonucleotides for the combination of chemical and enzymatic RNA synthesis | |
| DE69920247D1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
| ATE163973T1 (de) | Antisense oligonukleotidhemmung von papillomavirus | |
| DE69815370D1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
| NO972868L (no) | Oligonukleotid-dendrimer konjugater | |
| ES2112062T3 (es) | Oligonucleotidos con actividad anti-citomegalovirus. | |
| WO2001020017A3 (en) | Metal cluster containing nucleotides and nucleic acids, and intermediates therefor | |
| DE60024464D1 (de) | Hohe dichte markierung von dns mit modifizierte oder chromophore tragende nukleotide und benutzte dns polymerasen | |
| DE69726276D1 (de) | In situ herstellung von nukleosid-phosphoramiditen und ihre verwendung in der oligonukleotidsynthese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |